Glenmark Pharmaceuticals Ltd 2018 AR2
The report highlights Glenmark Pharmaceuticals' achievements during its 40th year of operations, transitioning towards an innovation-led global pharmaceutical company. In FY 2017-18, the company achieved flat revenues of INR 91,944.70 million on a consolidated Ind AS basis, while advancing its specialty and innovative pipeline, including the filing of Ryaltris with the US FDA. Glenmark expanded its global manufacturing footprint to 16 facilities across four continents and achieved zero liquid discharge at five of its plants. Additionally, the company positively impacted over one million lives through its corporate social responsibility initiatives focused on child health and sustainable livelihoods.
Company: Glenmark Pharmaceuticals Ltd
Sector: Manufacturing
Country: India
Year: 2018
Type: AR2
Pages: 316
Back to company
Glenmark Pharmaceuticals Ltd
Annual Report
The report highlights Glenmark Pharmaceuticals' achievements during its 40th year of operations, transitioning towards an innovation-led global pharmaceutical company. In FY 2017-18, the company achieved flat revenues of INR 91,944.70 million on a consolidated Ind AS basis, while advancing its specialty and innovative pipeline, including the filing of Ryaltris with the US FDA. Glenmark expanded its global manufacturing footprint to 16 facilities across four continents and achieved zero liquid discharge at five of its plants. Additionally, the company positively impacted over one million lives through its corporate social responsibility initiatives focused on child health and sustainable livelihoods.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Apr 1, 2017 - Mar 31, 2018
Fiscal Year
2018
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees